Cargando…

Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates

Detalles Bibliográficos
Autor principal:	Masuda, Daisaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164602/ https://www.ncbi.nlm.nih.gov/pubmed/36216574 http://dx.doi.org/10.5551/jat.ED216

Ejemplares similares

Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
por: Kim, Nam Hoon, et al.
Publicado: (2020)

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Lagrangian Fibrations
por: Huybrechts, D., et al.
Publicado: (2022)

Fibrates consistently lower risk of cardiovascular events across high-risk groups
por: Aalbers, J
Publicado: (2010)

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
por: Araki, Eiichi, et al.
Publicado: (2019)

Classifying spaces and fibrations
por: May, J Peter
Publicado: (1975)

Fibrations in CICY Threefolds
por: Anderson, Lara B., et al.
Publicado: (2017)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Distinguishing Elliptic Fibrations with AI
por: He, Yang-Hui, et al.
Publicado: (2019)

Torus fibrations, gerbes, and duality
por: Donagi, Ron, et al.
Publicado: (2008)

U-branes and $T^3$ fibrations
por: Liu, James T., et al.
Publicado: (1997)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
por: Sasaki, Yusuke, et al.
Publicado: (2020)

On C(ℵ)-Fibrations in Bitopological Semigroups
por: Dawood, Suliman, et al.
Publicado: (2014)

D-Branes on K3-Fibrations
por: Kaste, P., et al.
Publicado: (1999)

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
por: Arai, Hidenori, et al.
Publicado: (2018)

Triglycerides and Cardiovascular Risk
por: Harchaoui, K.E.L, et al.
Publicado: (2009)

Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study
por: Ho, Wen-Yu, et al.
Publicado: (2022)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Astaxanthin plus berberine: a nutraceutical strategy for replicating the benefits of a metformin/fibrate regimen in metabolic syndrome
por: DiNicolantonio, James J, et al.
Publicado: (2019)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia
por: Fujioka, Yoshio
Publicado: (2018)

Protective role of fibrates in cardiac ischemia/reperfusion
por: Singh, G., et al.
Publicado: (2012)

Pleiotropic effect of fibrates on senescence and autophagy in osteoarthritis
por: Szychlinska, Marta Anna, et al.
Publicado: (2019)

Exceptional SW Geometry from ALE Fibrations
por: Lerche, W., et al.
Publicado: (1996)

Fibrations and bundles with Hilbert cube manifold fibers
por: Torunczyk, Henryk, et al.
Publicado: (1989)

Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging
por: Murata, Yu, et al.
Publicado: (2023)

SUN-071 Unexpected Paradoxical Extremely Low of HDL-Cholesterol Level in a Non-Diabetes, Non-CKD Patient after Treatment with Specific Fibrate and Statin and Specific Fibrate Alone
por: Kiatpanabhikul, Phatharaporn
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uad32f2t3liqre4ci89fsb14ov